A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 513 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma August 2, 2018 Woman Develops Breast Cancer After Double Mastectomy, Has to Have the... May 19, 2021 Easy Meals at Home October 23, 2020 What to Know About Exercising During Prostate Cancer: An Expert Q&A August 8, 2023 Load more HOT NEWS Can we grow the treatments of tomorrow? – That Cancer Conversation A bug in the system – the difficulties of linking the... Better together: improving brain tumour treatment Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with...
